{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:33:02Z","timestamp":1791977582428,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire International GmbH"},{"name":"Shionogi & Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To assess the safety and efficacy of long-term administration of guanfacine extended-release (GXR) in adults with attention-deficit\/hyperactivity disorder (ADHD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this open-label, long-term, phase 3 extension study in Japan, 150 patients transitioned from a double-blind trial, and 41 newly enrolled patients received once daily GXR (starting dose 2\u2009mg\/day, maintenance dose 4\u20136\u2009mg\/day) for 50\u2009weeks. Primary outcome measures were the frequency and nature of treatment-emergent adverse events (TEAEs); secondary outcome measures included the change from week 0 in ADHD Rating Scale IV with Adult Prompts (ADHD-RS-IV; Japanese version) total and subscale scores, Conners\u2019 Adult ADHD Rating Scales (CAARS), Clinical Global Impression-Improvement (CGI-I) and Patient Global Impression-Improvement (PGI-I) scales, and quality of life (QoL) and executive functioning measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of all patients, 94.2% (180\/191) reported \u22651 TEAE and 19.9% (38\/191) discontinued because of a TEAE. Most TEAEs were mild to moderate in severity; there were two serious TEAEs and no deaths. Commonly reported TEAEs (\u226510% of patients) were somnolence, thirst, nasopharyngitis, decreased blood pressure, postural dizziness, bradycardia, malaise, constipation, and dizziness. Mean changes from week 0 in ADHD-RS-IV total and subscale scores and CAARS subscale scores were significantly improved in former placebo or GXR patients and new patients at last observation (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0001), and the percentage of patients with very much or much improved CGI-I and PGI-I scores increased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There were no major safety concerns during long-term GXR administration in adults with ADHD. After long-term treatment, patients had significant improvements from baseline in ADHD symptoms, QoL, and executive functioning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Japan Primary Registries Network (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/rctportal.niph.go.jp\/en\/\">https:\/\/rctportal.niph.go.jp\/en\/<\/jats:ext-link>): JapicCTI-163232, registered 04\/21\/2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-020-02867-8","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T10:02:58Z","timestamp":1601632978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and efficacy of guanfacine extended-release in adults with attention-deficit\/hyperactivity disorder: an open-label, long-term, phase 3 extension study"],"prefix":"10.1186","volume":"20","author":[{"given":"Akira","family":"Iwanami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Okutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"issue":"1","key":"2867_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12402-016-0208-3","volume":"9","author":"J Fayyad","year":"2017","unstructured":"Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, Andrade LH, Borges G, de Girolamo G, Florescu S, et al. The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization world mental health surveys. Atten Defic Hyperact Disord. 2017;9(1):47\u201365.","journal-title":"Atten Defic Hyperact Disord."},{"issue":"3","key":"2867_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","volume":"194","author":"V Simon","year":"2009","unstructured":"Simon V, Czobor P, B\u00e1lint S, M\u00e9sz\u00e1ros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204\u201311.","journal-title":"Br J Psychiatry"},{"issue":"10","key":"2867_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1176\/appi.ajp.2015.14101266","volume":"172","author":"TE Moffitt","year":"2015","unstructured":"Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M, Harrington H, Hogan S, Meier MH, Polanczyk GV, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry. 2015;172(10):967\u201377.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2867_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.157.5.816","volume":"157","author":"J Biederman","year":"2000","unstructured":"Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816\u20138.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2867_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/S003329170500471X","volume":"36","author":"SV Faraone","year":"2006","unstructured":"Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159\u201365.","journal-title":"Psychol Med"},{"key":"2867_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-244X-10-67","volume":"10","author":"SJ Kooij","year":"2010","unstructured":"Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry. 2010;10:67.","journal-title":"BMC Psychiatry"},{"issue":"12","key":"2867_CR7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1177\/1087054713518240","volume":"20","author":"B Pi\u00f1eiro-Dieguez","year":"2016","unstructured":"Pi\u00f1eiro-Dieguez B, Balanz\u00e1-Mart\u00ednez V, Garc\u00eda-Garc\u00eda P, Soler-L\u00f3pez B, CAT Study Group. Psychiatric comorbidity at the time of diagnosis in adults with ADHD: the CAT study. J Atten Disord. 2016;20(12):1066\u201375.","journal-title":"J Atten Disord"},{"issue":"3","key":"2867_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1087054716669589","volume":"22","author":"JT Instanes","year":"2018","unstructured":"Instanes JT, Klungs\u00f8yr K, Halm\u00f8y A, Fasmer OB, Haavik J. Adult ADHD and comorbid somatic disease: a systematic literature review. J Atten Disord. 2018;22(3):203\u201328.","journal-title":"J Atten Disord"},{"issue":"5\u20136","key":"2867_CR9","first-page":"10","volume":"9","author":"R Agarwal","year":"2012","unstructured":"Agarwal R, Goldenberg M, Perry R, IsHak WW. The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci. 2012;9(5\u20136):10\u201321.","journal-title":"Innov Clin Neurosci"},{"issue":"1","key":"2867_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1017\/S0033291706008713","volume":"37","author":"SL Able","year":"2007","unstructured":"Able SL, Johnston JA, Adler LA, Swindle RW. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1):97\u2013107.","journal-title":"Psychol Med"},{"issue":"9983","key":"2867_CR11","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/S0140-6736(14)61684-6","volume":"385","author":"S Dalsgaard","year":"2015","unstructured":"Dalsgaard S, \u00d8stergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190\u20136.","journal-title":"Lancet."},{"issue":"3","key":"2867_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12402-014-0150-1","volume":"6","author":"K Furczyk","year":"2014","unstructured":"Furczyk K, Thome J. Adult ADHD and suicide. Atten Defic Hyperact Disord. 2014;6(3):153\u20138.","journal-title":"Atten Defic Hyperact Disord"},{"key":"2867_CR13","doi-asserted-by":"crossref","unstructured":"Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Efficacy and safety of guanfacine extended release in treatment of attention deficit\/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2020;81(3):19m12979. https:\/\/doi.org\/10.4088\/JCP.19m12979.","DOI":"10.4088\/JCP.19m12979"},{"issue":"9","key":"2867_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"key":"2867_CR15","unstructured":"National Institute for Care and Health Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2018, last updated September 2019. https:\/\/www.nice.org.uk\/guidance\/ng87\/chapter\/Recommendations. Accessed 3 Mar 2020."},{"key":"2867_CR16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, 5th ed (DSM-5)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed (DSM-5). Washington, DC: American Psychiatric Publishing; 2013."},{"key":"2867_CR17","volume-title":"Conners\u2019 adult ADHD rating scales (CAARS)","author":"K Conners","year":"1999","unstructured":"Conners K, Erhardt D, Sparrow E. Conners\u2019 adult ADHD rating scales (CAARS). New York: Multi-Health Systems; 1999."},{"key":"2867_CR18","volume-title":"ADHD rating scale-IV: checklists, norms, and clinical interpretation","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press; 1998."},{"key":"2867_CR19","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impressions. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville: National Institute for Mental Health; 1976. p. 218\u201322."},{"issue":"4","key":"2867_CR20","first-page":"399","volume":"60","author":"H Ichikawa","year":"2018","unstructured":"Ichikawa H, Saito K, Saito T, Kariya N, Kodaira M, Ohta H, Kishida I, Mikami K, Ota T, Kyo M, et al. Reliability and validity of the ADHD-RS-IV with adult prompts: the Japanese version. Clin Psychiatry. 2018;60(4):399\u2013409.","journal-title":"Clin Psychiatry"},{"issue":"1","key":"2867_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11136-005-8325-z","volume":"15","author":"M Brod","year":"2006","unstructured":"Brod M, Johnston J, Able S, Swindle R. Validation of the adult attention-deficit\/hyperactivity disorder quality-of-life scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006;15(1):117\u201329.","journal-title":"Qual Life Res"},{"issue":"9","key":"2867_CR22","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s11136-007-9254-9","volume":"16","author":"LS Matza","year":"2007","unstructured":"Matza LS, Johnston JA, Faries DE, Malley KG, Brod M. Responsiveness of the adult attention-deficit\/hyperactivity disorder quality of life scale (AAQoL). Qual Life Res. 2007;16(9):1511\u201320.","journal-title":"Qual Life Res"},{"key":"2867_CR23","volume-title":"Behavior rating inventory of executive function\u2013adult version","author":"RM Roth","year":"2005","unstructured":"Roth RM, Isquith PK, Gioia GA. Behavior rating inventory of executive function\u2013adult version. Lutz: Psychological Assessment Resources; 2005."},{"key":"2867_CR24","unstructured":"Shire US. Intuniv\u00ae (guanfacine) [prescribing information]. Lexington; 2017."},{"issue":"12","key":"2867_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1017\/S1092852900017107","volume":"13","author":"J Biederman","year":"2008","unstructured":"Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047\u201355.","journal-title":"CNS Spectr"},{"issue":"10","key":"2867_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00787-018-1113-4","volume":"27","author":"M Huss","year":"2018","unstructured":"Huss M, Dirks B, Gu J, Robertson B, Newcorn JH, Ramos-Quiroga JA. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018;27(10):1283\u201394.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"2867_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/cap.2008.0080","volume":"19","author":"FR Sallee","year":"2009","unstructured":"Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215\u201326.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"2867_CR28","first-page":"1093","volume":"21","author":"H Ichikawa","year":"2018","unstructured":"Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Okutsu D, Saito K. Efficacy and safety of guanfacine hydrochloride extended-release tablet for children and adolescents with ADHD: a phase 2\/3 placebo-controlled, double-blind study in Japan [in Japanese]. Jpn J Clin Psychopharmacol. 2018;21(8):1093\u2013117.","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"12","key":"2867_CR29","first-page":"1645","volume":"21","author":"H Ichikawa","year":"2018","unstructured":"Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Okutsu D, Saito K. Long-term safety and efficacy of guanfacine hydrochloride extended-release tablet for children and adolescents with ADHD: a phase 2\/3 long-term, open-label extension study in Japan. [in Japanese]. Jpn J Clin Psychopharmacol. 2018;21(12):1645\u201361.","journal-title":"Jpn J Clin Psychopharmacol."},{"key":"2867_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.psychres.2015.12.017","volume":"236","author":"ME Butterfield","year":"2016","unstructured":"Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: a double blind, placebo-controlled study. Psychiatry Res. 2016;236:136\u201341.","journal-title":"Psychiatry Res"},{"issue":"4","key":"2867_CR31","first-page":"301","volume":"53","author":"P Martin","year":"2015","unstructured":"Martin P, Satin L, Kahn RS, Robinson A, Corcoran M, Purkayastha J, Youcha S, Ermer JC. A thorough QT study of guanfacine. Int J Clin Pharmacol Ther. 2015;53(4):301\u201316.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"2867_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40261-017-0527-y","volume":"37","author":"Y Matsuo","year":"2017","unstructured":"Matsuo Y, Okita M, Ermer J, Wajima T. Pharmacokinetics, safety, and tolerability of single and multiple doses of guanfacine extended-release formulation in healthy Japanese and Caucasian male adults. Clin Drug Investig. 2017;37(8):745\u201353.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"2867_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4088\/JCP.11m07529","volume":"73","author":"J Biederman","year":"2012","unstructured":"Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV. Adult outcome of attention-deficit\/hyperactivity disorder: a controlled 16-year follow-up study. J Clin Psychiatry. 2012;73(7):941\u201350.","journal-title":"J Clin Psychiatry"}],"updated-by":[{"DOI":"10.1186\/s12888-020-02965-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000}}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02867-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:07:40Z","timestamp":1633133260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02867-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the following local ethics committee: Mizuo Clinic Institutional Review Board (IRB); Ehime University Hospital IRB; IHL Shinagawa East One Medical Clinic IRB; Dr. Mano Medical Clinic IRB; Odori Park Mental Clinic IRB; Tokyo Midtown Clinic IRB; Tokyo-Eki Center-Building Clinic IRB; Riverside Internal and Circulatory Medical Clinic IRB; Goryokai Hospital IRB; Himorogi Psychiatric Institute IRB; Nanko Clinic of Psychiatry IRB; Iwata Buddy\u2019s Clinic IRB; Suzuki Internal and Circulatory Medical Clinic IRB; Kojinkai Sapporo Skin Clinic IRB; Shoda Hospital IRB; Kondo Hospital IRB; Tomisaka Clinic IRB; Yokohama Sakae Kyosai Hospital IRB; Hokkaido University Hospital IRB; Yamate Dermatological Clinic IRB; Chibune General Hospital IRB; IRB of Showa University Karasuyama Hospital; Yoyogi Mental Clinic IRB; Tokai University Hospital IRB; The Jikei University Hospital IRB for Medicinal Products; Non-Profit Organization Tokyo Allergy and Respiratory Disease Research Institute IRB; Review Board of Human Rights and Ethics for Clinical Studies; Nara Medical University Hospital IRB; University of Fukui Hospital IRB; Hayashi Diabetes Clinic IRB. All patients provided written informed consent before participating in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AI has received honoraria and other payments from Eisai, Eli Lilly Japan, Janssen Japan, Kyowa, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD K.K., Otsuka, Pfizer Japan, Sumitomo Dainippon Pharma, and Yoshitomiyakuhin Corporation. KS has received honoraria and other payments from Eli Lilly Japan, Hisamitsu, Janssen Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka, Shionogi, Shire Japan (now part of the Takeda group of companies), Sumitomo Dainippon Pharma, Taisho, and Yoshitomiyakuhin Corporation. MF and DO are employees of and own shares in Shionogi. HI has received honoraria and other payments from AbbVie GK, Eli Lilly Japan, Hisamitsu Pharmaceutical, Janssen Japan, Meiji Seika Pharma, Otsuka, Shionogi, and Taisho.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"485"}}